title: Low immunogenicity of seasonal trivalent influenza vaccine among patients receiving docetaxel for a solid tumour: results of a prospective pilot study.
abstract: BACKGROUND
  Patients receiving cytotoxic therapy for solid tumours are at risk of severe influenza. However, few data are available regarding the immunogenical efficacy of influenza vaccine in these patients.
  
  
  METHODS
  In this prospective study, 25 patients with breast (n=13) or prostate (n=12) cancer received a trivalent inactivated influenza vaccine along with docetaxel (Taxotere) administration. The influenza virus type A and B antibody titres were measured using haemagglutinin inhibition (Garten et al, 2009) before and 21 days after the vaccination. Seroconversion rate was defined as the percentage of patients with an increase in the serum titres ≥ 4 after vaccination.
  
  
  RESULTS
  Median age was 65 years (range: 33-87 years); 52% were females. Seroconversion rates were low: 28% (95% CI: 23.1-33.3) for H1N1, 8% (95% CI: 7.7-8.3) for H3N2 and 16% (95% CI: 7.7-25) for the B strain. The geometric mean titres ratios were 2.16 (H1N1), 1.3 (H3N2) and 1.58 (B). No serious adverse event (AE) related to the vaccine was reported. All the reported AE were from mild-to-moderate intensity.
  
  
  CONCLUSIONS
  In the patients receiving docetaxel for solid tumours, influenza vaccine triggers an immune response in only one third. Strategies using more immunogenic influenza vaccines must be evaluated in such patients.
authors.affiliation: Université Paris Descartes, Faculté de Médecine, Inserm CIC BT505, Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Cochin Saint Vincent de Paul, CIC de Vaccinologie Cochin-Pasteur, 27 rue du Faubourg Saint Jacques, Paris, 75014, France. pierre.loulergue@cch.aphp.fr
authors.forename: P
authors.initials: P
authors.lastname: Loulergue
authors.forename: J
authors.initials: J
authors.lastname: Alexandre
authors.forename: I
authors.initials: I
authors.lastname: Iurisci
authors.forename: S
authors.initials: S
authors.lastname: Grabar
authors.forename: J
authors.initials: J
authors.lastname: Medioni
authors.forename: S
authors.initials: S
authors.lastname: Ropert
authors.forename: V
authors.initials: V
authors.lastname: Dieras
authors.forename: F
authors.initials: F
authors.lastname: Le Chevalier
authors.forename: S
authors.initials: S
authors.lastname: Oudard
authors.forename: F
authors.initials: F
authors.lastname: Goldwasser
authors.forename: P
authors.initials: P
authors.lastname: Lebon
authors.forename: O
authors.initials: O
authors.lastname: Launay
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000096:biosynthesis*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077143:Docetaxel; D005260:Female; D006387:Hemagglutination, Viral; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology; D007252:Influenza Vaccines / Q000009:adverse effects / Q000276:immunology*; D029524:Betainfluenzavirus / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000914:Antibodies, Viral; D000970:Antineoplastic Agents; D007252:Influenza Vaccines; D043823:Taxoids; D000077143:Docetaxel